SynthesisFrontiers in endocrinology2026
Influence of diabetes on survival of patients with glioma: a meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic impact of preexisting diabetes on glioma survival remains unclear, with conflicting evidence across studies. This meta-analysis aimed to assess the association between diabetes and survival outcomes in patients with glioma. Methods: We systematically searched PubMed, Embase, and Web of Science up to April 30, 2025, for cohort studies reporting hazard ratios (HRs) for overall survival (OS) or progression-free survival (PFS) in glioma patients with and without preexisting diabetes. A random-effects model was used to pool multivariate-adjusted HRs accounting for the possible influence of heterogeneity. Results: Twelve retrospective cohort studies comprising 8,948 patients were included. Eleven studies reported on OS, and four on PFS. Pooled analysis showed that preexisting diabetes was associated with poorer OS (HR: 1.22, 95% CI: 1.10-1.36, p < 0.001; I² = 33%). Sensitivity analysis confirmed result robustness (HR range: 1.18-1.26). Subgroup analyses revealed consistent associations regardless of tumor grade (Grade III-IV: HR: 1.42; GBM: HR: 1.19; p for subgroup difference = 0.47), age (< 60 vs. ≥ 60 years, p = 0.15), sex distribution (< 60% vs. ≥ 60% men, p = 0.91), diabetes type (type 2 vs. overall diabetes, p = 0.33), or follow-up duration (≤ 12 vs. >12 months, p = 0.69). Preexisting diabetes was also associated with poorer PFS (HR: 1.36, 95% CI: 1.01-1.83, p = 0.04; I² = 0%). Conclusions: Preexisting diabetes is associated with reduced survival in glioma patients. These findings highlight the importance of integrating metabolic comorbidities into glioma prognostic assessment. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251086248, identifier CRD420251086248.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.